Abstract
Dermatan sulfate (DS) is well-known for its anticoagulant activity through binding to heparin cofactor II (HCII) to enhance thrombin inhibition. It has also been reported that DS has a profibrinolytic effect. We have evaluated the effects of DS solutions (4–20 μg/mL) on the formation (by kinetic studies), structure (by electron microscopy and compaction assays) and lysis (with urokinase-type plasminogen activator) of plasma fibrin networks. The results showed that DS significantly prolonged the lag phase and decreased the fibrin formation rate and the optical density of the final networks versus control, in a concentration dependent way. DS-associated networks presented a minor network percentage compared with control, composed of lower number of fibers per field, which resulted significantly thinner and longer. Moreover, DS rendered gels more sensible to rupture by centrifugal force and more susceptible to lysis. When fibrin formation kinetic assays were performed with purified fibrinogen instead of plasma, in the absence of HCII, the optical density of final DS-associated networks was statistically lower than control. Therefore, a direct effect of DS on the thickness of fibers was observed. Since in all in vitro assays low DS concentrations were used, it could be postulated that the fibrin features described above are plausible to be found in in vivo thrombi and therefore, DS would contribute to the formation of less thrombogenic clots.
Similar content being viewed by others
References
Casu B (1991) Structural features and binding properties of chondroitin sulfate, dermatan sulfate and heparan sulfate. Semin Thromb Hemost 17:9–14
Andrew M, Mitchell L, Berry L, Paes B, Delorme M, Ofosu F, Burrows R, Khambalia B (1992) An anticoagulant dermatan sulfate proteoglycan circulates in the pregnant woman and her fetus. J Clin Invest 89:321–326
Delorme MA, Saees N, Sevick A, Mitchell L, Berry L, Johnston M, Andrew M (1993) Plasma dermatan sulfate proteoglycan in a patient on chronic hemodialysis. Blood 82:3380–3385
Rossi E, Duboscq C, Peragallo M, Kordich L (1997) Heparin cofactor II (HC II) and dermatan sulfate plasmatic levels in acute burnt patients. Thromb Haemost Suppl:435
Saito A, Munakata H (2007) Analysis of plasma proteins that binds to glycosaminoglycans. Biochim Biophys Acta 1770:241–246
Rau J, Mitchell J, Fortenberry Y, Church F (2011) Heparin cofactor II: discovery, properties, and role in controlling vascular homeostasis. Semin Thromb Hemost 37:339–348
Tovar AM, de Mattos DA, Stelling MP, Sarcinelli-Luz BS, Nazareth RA, Mourão PA (2005) Dermatan sulfate is the predominant antithrombotic glycosaminoglycan in vessel walls: implications for a possible physiological function of heparin cofactor II. Biochim Biophys Acta 1740:45–53
Han JH, Cote HCF, Tollefsen DM (1997) Inhibition of meizothrombin and meizothrombin(des F1) by heparin cofactor II. J Biol Chem 272:28660–28665
Liaw PC, Becker DL, Stafford AR, Fredenburgh JC, Weitz JI (2001) Molecular basis for the susceptibility of fibrin-bound thrombin to inactivation by heparin cofactor II in the presence of dermatan sulfate but not heparin. J Biol Chem 276:20959–22065
Iacoviello L, D’Adamo MC, Pawlak K, Polishchuck R, Wollny T, Buczko W, Donati MB (1996) Antithrombotic activity of dermatan sulphates, heparins and their combination in an animal model of arterial thrombosis. Thromb Haemost 76:1102–1107
Carrie D, Caranobe C, Gabaig AM, Larroche M, Boneu B (1992) Effects of heparin, dermatan sulphate and of their association on the inhibition of venous thrombosis growth in the rabbit. Thromb Haemost 68:637–641
Attanasio E, Russo P, Carunchio G, Caprino L (2001) Dermatan sulfate versus unfractionated heparin for the prevention of venous thromboembolism in patients undergoing surgery for cancer. A cost-effectiveness analysis. Pharmacoeconomics 19:57–68
Imberti D, Verso M, Silvestrini E, Taliani MR, Agnelli G (2003) Successful treatment with dermatan sulfate in six patients with heparin-induced thrombocytopenia and acute venous thromboembolism. J Thromb Haemost 1:2696–2697
Castañon MM, Gamba C, Kordich LC (2007) Insight into the profibrinolytic activity of dermatan sulfate: effects on the activation of plasminogen mediated by tissue and urinary plasminogen activators. Thromb Res 120:745–752
Stirling Y, Woolf L, North W, Seghatchian MJ, Meade TW (1984) Haemostasis in normal pregnancy. Thromb Haemost 52:176–182
Wickström K, Edelstam G, Löwbeer C, Hansson L, Siebahn A (2004) Reference intervals for plasma levels of fibrinectin, von Willebrand factor, free protein S and antithrombin during third-trimester pregnancy. Scand J Clin Lab Invest 64:31–40
Delorme M, Burrows R, Ofosu F, Andrew M (1992) Thrombin regulation in mother and fetus during pregnancy. Semin Thromb Hemost 18:81–90
Andersson T, Lorentzen B, Hogdahl H, Clausen T, Mowinckel MC, Abildgaard U (1996) Thrombin-inhibitor complexes in the blood during and after delivery. Thromb Res 82:109–117
Giri TK, Tollefsen DM (2006) Placental dermatan sulfate: isolation, anticoagulant activity, and association with heparin cofactor II. Blood 107:2753–2758
Weisel JW, Litvinov RI (2008) The biochemical and physical process of fibrinolysis and effects of clots structure and stability on the lysis rate. Cardiovasc Hematol Agents Med Chem 6:161–180
Lauricella AM, Quintana I, Castañon M, Sassetti B, Kordich L (2006) Influence of homocysteine on fibrin network lysis. Blood Coagul Fibrinolysis 17:181–186
Nair CH, Shats EA (1997) Compaction as a method to characterize fibrin network structure: kinetic studies and relationship to crosslinking. Thromb Res 88:381–387
Colliec S, Fischer AM, Tapon-Bretaudiere J, Boisson C, Durand P, Jozefonvicz J (1991) Anticoagulant properties of a fucoidan fraction. Thromb Res 64:143–154
Weisel JW, Veklich Y, Collet JP, Francis CW (1999) Structural studies of fibrinolysis by electron and light microscopy. Thromb Haemost 82:277–282
Wolberg AS, Gabriel DA, Hoffman M (2002) Analysing fibrin clot structure using a microplate reader. Blood Coagul Fibrinolysis 13:533–539
Jones M, Gabriel DA (1988) Influence of subendothelial basement membrane components on fibrin assembly. J Biol Chem 263:7043–7048
Litvinov RI, Yakovlev S, Tsurupa G, Gorkun OV, Medved L, Weisel JW (2007) Direct evidence for specific interactions of the fibrinogen alphaC-domains with the central E region and with each other. Biochemistry 46:9133–9142
Weisel J (2007) Structure of fibrin: impact on clot stability. J Thromb Haemost 5(Suppl. 1):116–124
Undas A, Ariëns R (2011) Fibrin clot structure and function. A role in the pathophysiology of arterial and venous thromboembolic diseases. Arterioscler Thromb Vasc Biol 31:88–99
Acknowledgments
This work was supported by a grant from the Universidad de Buenos Aires (UBACyT 01/W998), Argentina.
Conflict of interest
All authors disclose any financial and personal relationships with other people or organizations that could inappropriately influence this work.
Author information
Authors and Affiliations
Corresponding author
Additional information
María Mercedes Castañon—in memory.
Rights and permissions
About this article
Cite this article
Lauricella, A.M., Castañon, M.M., Kordich, L.C. et al. Alterations of fibrin network structure mediated by dermatan sulfate. J Thromb Thrombolysis 35, 257–263 (2013). https://doi.org/10.1007/s11239-012-0804-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11239-012-0804-9